Thus, we determined the Siglec‐10 surface expression on CLL cells (gated as CD20low CD5+) and the corresponding normal residual B cells (gated as CD20high CD5−, Fig EV5A) from patient blood samples in a cohort of 73 CLL cases. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.